Name a broad-spectrum antiviral agent.

Name a broad-spectrum antiviral agent.

• A. Ribavirin
• B. Acyclovir
• C. Favipiravir
• D. Oseltamivir

Answer: (C)

Favipiravir is recognized as a broad-spectrum antiviral agent due to its efficacy against a wide range of RNA viruses. This includes viruses responsible for diseases such as influenza, Ebola, and several other viral infections. It works by inhibiting viral RNA polymerase, an essential enzyme that the virus requires for replication. This mechanism allows Favipiravir to be effective in treating infections caused by various viral pathogens. In contrast, substances like ribavirin, acyclovir, and oseltamivir target more specific types of viruses. Ribavirin is mainly used against certain RNA viruses and has limited effectiveness against others. Acyclovir is specifically effective against herpesviruses, particularly HSV and VZV. Oseltamivir, on the other hand, is an antiviral that is primarily used to treat and prevent influenza A and B viruses. Thus, these agents are not classified as broad-spectrum because their activity is limited to specific viral families, whereas Favipiravir's broader activity profile sets it apart as a versatile treatment option.

Favipiravir is recognized as a broad-spectrum antiviral agent due to its efficacy against a wide range of RNA viruses. This includes viruses responsible for diseases such as influenza, Ebola, and several other viral infections. It works by inhibiting viral RNA polymerase, an essential enzyme that the virus requires for replication. This mechanism allows Favipiravir to be effective in treating infections caused by various viral pathogens.

In contrast, substances like ribavirin, acyclovir, and oseltamivir target more specific types of viruses. Ribavirin is mainly used against certain RNA viruses and has limited effectiveness against others. Acyclovir is specifically effective against herpesviruses, particularly HSV and VZV. Oseltamivir, on the other hand, is an antiviral that is primarily used to treat and prevent influenza A and B viruses. Thus, these agents are not classified as broad-spectrum because their activity is limited to specific viral families, whereas Favipiravir's broader activity profile sets it apart as a versatile treatment option.